01 March 2025 : Clinical Research
Time-Sensitive Antibiotic Adjustments in Gram-Negative Bacteremia: A Survival Perspective
Yunwei Zheng ABCDEF 1, Chuwen Zhao ABCDEF 1,2, Bo Liao EF 3, Fuxing Li ABC 1, Yaping Hang ACD 1, Junqi Zhu BCE 1,2, Youling Fang CDF 1,2, Yanhua Liu BDEF 1, Longhua Hu ADEG 1*DOI: 10.12659/MSM.945569
Med Sci Monit 2025; 31:e945569
Table 3 Empirical antibiotic treatment between the 2 groups before and after propensity score-matched (PSM) analysis.
| Treatment parameter | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| AEAT (n=457) | IEAT (n=179) | P | AEAT (n=109) | IEAT (n=109) | P | |
| Monotherapy | 309 (71.69) | 124 (69.27) | 0.549 | 83 (76.15) | 91 (83.49) | 0.177 |
| Combination therapy | 122 (28.31) | 55 (30.73) | 26 (23.85) | 18 (16.51) | ||
| Aminoglycosides | 3 (0.70) | 1 (0.56) | >0.999 | 0 (0) | 0 (0) | – |
| Penicillins | 198 (45.94) | 34 (18.99) | <0.001 | 54 (49.54) | 12 (11.01) | <0.001 |
| Carbapenems | 113 (26.22) | 36 (20.11) | 0.110 | 24 (22.02) | 6 (5.50) | <0.001 |
| Fluoroquinolones | 90 (20.88) | 59 (32.96) | 0.002 | 20 (18.35) | 35 (32.11) | 0.019 |
| Tetracyclines | 1 (0.23) | 0 (0) | >0.999 | 0 (0) | 0 (0) | – |
| First-generation cephalosporins | 1 (0.23) | 2 (1.12) | 0.207 | 1 (0.92) | 2 (1.83) | >0.999 |
| Second-generation cephalosporins | 22 (5.10) | 13 (7.26) | 0.297 | 5 (4.59) | 6 (5.50) | 0.757 |
| Third-generation cephalosporins | 131 (30.39) | 91 (50.84) | <0.001 | 31 (28.44) | 61 (55.96) | <0.001 |
| Fourth-generation cephalosporins | 2 (0.46) | 1 (0.56) | >0.999 | 1 (0.92) | 1 (0.92) | >0.999 |